Planegg – Medigene AG (MDG1, Frankfurt, Prime Standard) announces that its CEO, Professor Dr. Dolores Schendel, was awarded the Bavarian Order of Merit (Bayerischer Verdienstorden).
The Bavarian Order of Merit is awarded on an annual basis as a recognition of outstanding contributions to the Free State of Bavaria and the Bavarian people and is a symbol of the outstanding engagement and extraordinary commitment of citizens to the community. The Bavarian Order of Merit was awarded yesterday by Prime Minister Dr. Markus Söder during a ceremony in Munich.
“I am incredibly honored to receive this distinction,” said Prof. Dr. Dolores Schendel, CEO of Medigene. “The Bavarian Order of Merit is an award that is steeped in tradition, service, and honor. I feel proud to join the ranks of past recipients of this special award and will continue working to provide treatment options for those suffering from life-threatening illnesses.”
Professor Schendel became Chief Executive Officer of Medigene in 2016 after previously serving as the Chief Scientific Officer of Medigene since 2014. From 1998 to 2013, Professor Schendel was Director of the Institute of Molecular Immunology at the Helmholtz Zentrum München (German Research Center for Health and Environment). Previously, she taught as a professor of immunology at the Munich Ludwig Maximilian University, specializing in human cellular immunology and T cell responses in the field of oncology. Professor Schendel is the author of more than 200 scientific publications and has been a member of expert panels of various research organizations for several decades, such as the German Research Foundation, the German Cancer Aid and the European Research Council. Prof. Dolores Schendel is the recipient of the Federal Cross of Merit and received the award of the German Cancer Aid ‘Deutsche Krebshilfe Preis 2016’.
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit http://www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 – 89 – 20 00 33 – 33 01